Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Trial Profile

Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms CAIRO2
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Oct 2016 Results (n=182) analysing copy number alterations as predictive biomarkers to bevacizumab response, presented at the 41st European Society for Medical Oncology Congress.
    • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top